View Cancer Clinical Trials
(Pediatric) Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase I/II Dose-Finding Study
|Blood & Marrow Transplant (BMT)
A. Primary Objectives
- Identify doses of total body irradiation (TBI) that lead to sufficient probability of donor engraftment (>5% donor CD3 chimerism) by day +200.
- Evaluate the probability of severe acute graft-versus-host disease.
B. Secondary Objectives
- Evaluate the probabilities of overall survival, regimen-related toxicity (RRT), and recurrent hematopoietic malignancy in those patients with a prior underlying history of such.
- Examine the degree to which mixed chimerism provides for amelioration of symptoms (ie, infections due to neutropenia, hemorrhage due to thrombocytopenia) associated with bone marrow failure
- Determine if the FA complementation group and % initial mosaicism predict engraftment and RRT outcomes
Patients must meet one of the following criteria (1-4) and 5 to be eligible for this study:
- Any patient with FA and BM failure involving 2 of the following 3 lineages: granulocyte count <0.5 x 10^9/L, platelet count <20 x 10^9/L, or hemoglobin <8 g/dL.
- Any patient with FA who requires red blood cell or platelet transfusions because of marrow failure
- Any patient with FA who has a life-threatening BM failure involving a single hematopoietic lineage.
- Any patient with FA and pre-existing cytogenetic abnormality including hematopoietic malignancy (AML or MDS) in morphological remission (defined as absence of circulating blasts and bone marrow blasts <5% as assessed by morphology). Note that hematopoietic recovery is not required for remission status.
- Patients must have a negative cytotoxic crossmatch with donor.
- Patients having available HLA-matched related donors.
- Significant organ dysfunction that would prevent compliance with conditioning, GVHD prophylaxis, or would severely limit the probability of survival, such as liver disease/failure (active hepatitis, moderate to severe portal fibrosis/cirrhosis confirmed by biopsy or uncorrectable hepatic synthetic dysfunction), lung disease, or cardiac disease (ejection fraction <35%, or if unable to obtain ejection fraction, shortening fraction of <26%; if shortening is <26% a cardiology consult is required with PI having final approval of eligibility).
- HIV seropositive patients
- Fertile females who are unwilling to use contraceptive techniques during and for the twelve months following treatment, as well as females who are pregnant or actively breast feeding
- Fertile males who are unwilling to use contraceptive techniques during and for the twelve months following treatment
- AML/MDS in morphological relapse, defined as having circulating blasts or bone marrow blasts ≥5% as assessed by morphology
- Active infectious disease concerns
- Karnofsky performance score <50 or Lansky performance score <40
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.